Overview

Evaluation of KX2-391 in Patients With Advanced Malignancies

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1 study is to determine the safety and tolerability of KX2-391 in cancer patients.
Phase:
Phase 1
Details
Lead Sponsor:
Athenex, Inc.
Kinex Pharmaceuticals Inc
Treatments:
Tirbanibulin